Physician profile
Ajay Kumar
NPI 1730461237
$2,667.02
in general payments reported to CMS, 2019-2025
27 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.34 · 2020: $45.27 · 2021: $88.71 · 2022: $554 · 2023: $419 · 2024: $738 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $424.78 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $420.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $207.49 | 2022-2025 | |
| Lilly USA, LLC | $192.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $137.02 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $102.43 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $97.21 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $96.55 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $78.48 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.82 | 2020-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $38.61 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $36.10 | 2025 | Camzyos, Eliquis |
| Acella Pharmaceuticals, LLC | $34.95 | 2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $28.37 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $25.72 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $23.14 | 2025 | Auvelity |
| Organon LLC | $21.85 | 2025 | Nexplanon |
| Averitas Pharma INC. | $19.20 | 2024 | Qutenza |
| Janssen Pharmaceuticals, INC | $16.99 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.50 | 2024 | Gvoke Hypopen |
| Ibsa Pharma INC. | $15.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.69 | 2022 | |
| Dexcom, INC. | $15.44 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $14.85 | 2021 | |
| Merck Sharp & Dohme LLC | $14.54 | 2023 | Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.